Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of LAS41007 versus vehicle and Solaraze in actinic keratosis
2010-022244-20Phase 3Terminated
- Sponsor
- Almirall
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LAS41007 in actinic keratosis (AK) (3 arms), sponsored by Almirall. Primary endpoint: Histological clearance of the second pre-selected target lesion. Started Sep 2010; status: terminated.
02
Drugs
LAS41007
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2010-022244-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022244-20.